ArticleACS omega2025
Human-Validated Neural Networks for Precise Amastigote Categorization and Quantification to Accelerate Drug Discovery in Leishmaniasis.
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Leishmaniases present a significant global health challenge with limited and often inadequate treatment options available. Traditional microscopic methods for detecting Leishmania amastigotes are time-consuming and error-prone, highlighting the need for automated approaches. This study aimed to implement and validate the YOLOv8 deep learning model for real-time detection, quantification, and categorization of Leishmania amastigotes to enhance drug screening assays. YOLOv8 was trained on 470 images from two microscopes, classifying them into categories such as "infected cells," "intracellular amastigotes," "uninfected cells," and "edge cells." The model's performance was compared to human operators using Pearson and Spearman correlation analyses. YOLOv8 achieved strong performance in detecting "infected cells" (AUC = 0.934) and "intracellular amastigotes" (AUC = 0.846). However, challenges remained in differentiating extracellular amastigotes from background noise (AUC = 0.672). Despite these challenges, the YOLOv8 model effectively minimized human variability in drug screening, providing a reliable and efficient tool for the quantification and categorization of Leishmania amastigotes in drug discovery efforts. While further refinements are required to resolve misclassification issues, the model demonstrates significant potential in enhancing both accuracy and throughput in preclinical assays.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.